Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Intrauterine fetal transfusion of red cells

Kenneth J Moise Jr, MD
Section Editors
Charles J Lockwood, MD, MHCM
Steven Kleinman, MD
Deputy Editor
Vanessa A Barss, MD, FACOG


The infusion of red blood cells into the fetus is one of the most successful in utero therapeutic procedures. Although never studied in randomized trials, observational studies have clearly demonstrated that intrauterine transfusion (IUT) of the severely anemic fetus improves survival. Universal use of prophylactic Rh(D) immune globulin has reduced the need for IUT dramatically; however, the procedure continues to be an essential modality for treatment of severe fetal anemia from a variety of causes, such as non-Rh(D) alloimmunization, parvovirus B19 infection, chronic fetomaternal hemorrhage, and homozygous alpha-thalassemia.


We consider pregnancies with severe fetal anemia at 18 to 35 weeks of gestation optimal candidates for IUT. We obtain fetal blood via percutaneous umbilical blood sampling for hematocrit/hemoglobin determination when the fetal middle cerebral artery peak systolic velocity is greater than 1.50 multiples of the median and perform the first IUT if fetal hemoglobin is two standard deviations below the mean value for gestational age (table 1). Intervention at this moderately reduced hemoglobin level results in a better fetal outcome than waiting until development of severe anemia (hemoglobin level more than 7 g/dL below the normal mean for gestational age [1]) or hydrops (actual hemoglobin level <5 g/dL) [2]. A hematocrit less than 30 percent can also be used as the threshold for fetal transfusion [3].

The procedure is generally limited to pregnancies between 18 and 35 weeks of gestation because before 18 weeks the small size of the relevant anatomic structures causes technical challenges and after 35 weeks IUT is considered riskier than delivery followed by postnatal transfusion therapy [4].

For the rare patient with very early (≤18 weeks) severe alloimmunization, plasma exchange and administration of intravenous immunoglobulin G may maintain the fetal hematocrit above life-threatening levels long enough to achieve a gestational age when IUT is technically feasible. A variety of therapeutic regimens have been described in case reports and small cases series [5].


Anonymous donor units — Red blood cells (RBCs) used for IUT should undergo the same testing that occurs for any red cell donor unit. The units are cross-matched with maternal blood to reduce the risk of sensitization to new red cell antigens. (See "Blood donor screening: Laboratory testing".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Dec 2016. | This topic last updated: Thu Jan 12 00:00:00 GMT 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Nicolaides KH, Soothill PW, Clewell WH, et al. Fetal haemoglobin measurement in the assessment of red cell isoimmunisation. Lancet 1988; 1:1073.
  2. Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000; 342:9.
  3. Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol 2008; 112:164.
  4. Klumper FJ, van Kamp IL, Vandenbussche FP, et al. Benefits and risks of fetal red-cell transfusion after 32 weeks gestation. Eur J Obstet Gynecol Reprod Biol 2000; 92:91.
  5. Papantoniou N, Sifakis S, Antsaklis A. Therapeutic management of fetal anemia: review of standard practice and alternative treatment options. J Perinat Med 2013; 41:71.
  6. Fung MK, Grossman MK, Hillyer CD, Westhoff CM. Technical manual of the American Association of Blood Banks, 18th ed, American Association of Blood Banks, Bethesda, Maryland 2014.
  7. Schonewille H, Prinsen-Zander KJ, Reijnart M, et al. Extended matched intrauterine transfusions reduce maternal Duffy, Kidd, and S antibody formation. Transfusion 2015; 55:2912.
  8. Viëtor HE, Kanhai HH, Brand A. Induction of additional red cell alloantibodies after intrauterine transfusions. Transfusion 1994; 34:970.
  9. Schonewille H, Klumper FJ, van de Watering LM, et al. High additional maternal red cell alloimmunization after Rhesus- and K-matched intrauterine intravascular transfusions for hemolytic disease of the fetus. Am J Obstet Gynecol 2007; 196:143.e1.
  10. Watson WJ, Wax JR, Miller RC, Brost BC. Prevalence of new maternal alloantibodies after intrauterine transfusion for severe Rhesus disease. Am J Perinatol 2006; 23:189.
  11. el-Azeem SA, Samuels P, Rose RL, et al. The effect of the source of transfused blood on the rate of consumption of transfused red blood cells in pregnancies affected by red blood cell alloimmunization. Am J Obstet Gynecol 1997; 177:753.
  12. Dodd JM, Windrim RC, van Kamp IL. Techniques of intrauterine fetal transfusion for women with red-cell isoimmunisation for improving health outcomes. Cochrane Database Syst Rev 2012; :CD007096.
  13. Harman CR, Bowman JM, Manning FA, Menticoglou SM. Intrauterine transfusion--intraperitoneal versus intravascular approach: a case-control comparison. Am J Obstet Gynecol 1990; 162:1053.
  14. Lewis M, Bowman JM, Pollock J, Lowen B. Absorption of red cells from the peritoneal cavity of an hydropic twin. Transfusion 1973; 13:37.
  15. Creasman WT, Duggan ER, Lund CJ. Absorption of transfused chromium-labeled erythrocytes from the fetal peritoneal cavity in hydrops fetalis. Am J Obstet Gynecol 1966; 94:586.
  16. Taylor WW, Scott DE, Pritchard JA. Fate of compatible adult erythrocytes in the fetal peritoneal cavity. Obstet Gynecol 1966; 28:175.
  17. Weiner CP, Wenstrom KD, Sipes SL, Williamson RA. Risk factors for cordocentesis and fetal intravascular transfusion. Am J Obstet Gynecol 1991; 165:1020.
  18. Van Kamp IL, Klumper FJ, Oepkes D, et al. Complications of intrauterine intravascular transfusion for fetal anemia due to maternal red-cell alloimmunization. Am J Obstet Gynecol 2005; 192:171.
  19. Westgren M, Selbing A, Stangenberg M. Fetal intracardiac transfusions in patients with severe rhesus isoimmunisation. Br Med J (Clin Res Ed) 1988; 296:885.
  20. Antsaklis AI, Papantoniou NE, Mesogitis SA, et al. Cardiocentesis: an alternative method of fetal blood sampling for the prenatal diagnosis of hemoglobinopathies. Obstet Gynecol 1992; 79:630.
  21. Fox C, Martin W, Somerset DA, et al. Early intraperitoneal transfusion and adjuvant maternal immunoglobulin therapy in the treatment of severe red cell alloimmunization prior to fetal intravascular transfusion. Fetal Diagn Ther 2008; 23:159.
  22. Nicolini U, Santolaya J, Ojo OE, et al. The fetal intrahepatic umbilical vein as an alternative to cord needling for prenatal diagnosis and therapy. Prenat Diagn 1988; 8:665.
  23. Nicolini U, Nicolaidis P, Fisk NM, et al. Fetal blood sampling from the intrahepatic vein: analysis of safety and clinical experience with 214 procedures. Obstet Gynecol 1990; 76:47.
  24. Giannakoulopoulos X, Sepulveda W, Kourtis P, et al. Fetal plasma cortisol and beta-endorphin response to intrauterine needling. Lancet 1994; 344:77.
  25. Moise KJ Jr, Carpenter RJ Jr, Kirshon B, et al. Comparison of four types of intrauterine transfusion: effect on fetal hematocrit. Fetal Ther 1989; 4:126.
  26. Nicolini U, Kochenour NK, Greco P, et al. When to perform the next intra-uterine transfusion in patients with Rh allo-immunization: combined intravascular and intraperitoneal transfusion allows longer intervals. Fetal Ther 1989; 4:14.
  27. Moise KJ Jr, Mari G, Fisher DJ, et al. Acute fetal hemodynamic alterations after intrauterine transfusion for treatment of severe red blood cell alloimmunization. Am J Obstet Gynecol 1990; 163:776.
  28. Forestier F, Daffos F, Catherine N, et al. Developmental hematopoiesis in normal human fetal blood. Blood 1991; 77:2360.
  29. Radunovic N, Lockwood CJ, Alvarez M, et al. The severely anemic and hydropic isoimmune fetus: changes in fetal hematocrit associated with intrauterine death. Obstet Gynecol 1992; 79:390.
  30. Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Mari G, Norton ME, et al. Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for anemia--diagnosis and management. Am J Obstet Gynecol 2015; 212:697.
  31. Welch R, Rampling MW, Anwar A, et al. Changes in hemorheology with fetal intravascular transfusion. Am J Obstet Gynecol 1994; 170:726.
  32. Dildy GA 3rd, Smith LG Jr, Moise KJ Jr, et al. Porencephalic cyst: a complication of fetal intravascular transfusion. Am J Obstet Gynecol 1991; 165:76.
  33. Drew JH, Guaran RL, Cichello M, Hobbs JB. Neonatal whole blood hyperviscosity: the important factor influencing later neurologic function is the viscosity and not the polycythemia. Clin Hemorheol Microcirc 1997; 17:67.
  34. Giannina G, Moise KJ Jr, Dorman K. A simple method to estimate volume for fetal intravascular transfusions. Fetal Diagn Ther 1998; 13:94.
  35. Mandelbrot L, Daffos F, Forestier F, et al. Assessment of fetal blood volume for computer-assisted management of in utero transfusion. Fetal Ther 1988; 3:60.
  36. Bowman JM. The management of Rh-Isoimmunization. Obstet Gynecol 1978; 52:1.
  37. Daffos F, Forestier F, Mac Aleese J, et al. Fetal curarization for prenatal magnetic resonance imaging. Prenat Diagn 1988; 8:312.
  38. Bernstein HH, Chitkara U, Plosker H, et al. Use of atracurium besylate to arrest fetal activity during intrauterine intravascular transfusions. Obstet Gynecol 1988; 72:813.
  39. Mouw RJ, Klumper F, Hermans J, et al. Effect of atracurium or pancuronium on the anemic fetus during and directly after intravascular intrauterine transfusion. A double blind randomized study. Acta Obstet Gynecol Scand 1999; 78:763.
  40. Scheier M, Hernandez-Andrade E, Fonseca EB, Nicolaides KH. Prediction of severe fetal anemia in red blood cell alloimmunization after previous intrauterine transfusions. Am J Obstet Gynecol 2006; 195:1550.
  41. Egberts J, van Kamp IL, Kanhai HH, et al. The disappearance of fetal and donor red blood cells in alloimmunised pregnancies: a reappraisal. Br J Obstet Gynaecol 1997; 104:818.
  42. Lobato G, Soncini CS. Fetal hematocrit decrease after repeated intravascular transfusions in alloimmunized pregnancies. Arch Gynecol Obstet 2007; 276:595.
  43. Mari G, Detti L, Oz U, et al. Accurate prediction of fetal hemoglobin by Doppler ultrasonography. Obstet Gynecol 2002; 99:589.
  44. Lobato G, Soncini CS. Fetal hydrops and other variables associated with the fetal hematocrit decrease after the first intrauterine transfusion for red cell alloimmunization. Fetal Diagn Ther 2008; 24:349.
  45. Detti L, Oz U, Guney I, et al. Doppler ultrasound velocimetry for timing the second intrauterine transfusion in fetuses with anemia from red cell alloimmunization. Am J Obstet Gynecol 2001; 185:1048.
  46. Moise KJ Jr. The usefulness of middle cerebral artery Doppler assessment in the treatment of the fetus at risk for anemia. Am J Obstet Gynecol 2008; 198:161.e1.
  47. Mari G, Zimmerman R, Segata M. Am J Obstet Gynecol 2005; 191:S149.
  48. Trevett TN Jr, Dorman K, Lamvu G, Moise KJ Jr. Antenatal maternal administration of phenobarbital for the prevention of exchange transfusion in neonates with hemolytic disease of the fetus and newborn. Am J Obstet Gynecol 2005; 192:478.
  49. Lepercq J, Poissonnier MH, Coutanceau MJ, et al. Management and outcome of fetomaternal Rh alloimmunization in twin pregnancies. Fetal Diagn Ther 1999; 14:26.
  50. Ghi T, Brondelli L, Simonazzi G, et al. Sonographic demonstration of brain injury in fetuses with severe red blood cell alloimmunization undergoing intrauterine transfusions. Ultrasound Obstet Gynecol 2004; 23:428.
  51. Nicolini U, Kochenour NK, Greco P, et al. Consequences of fetomaternal haemorrhage after intrauterine transfusion. BMJ 1988; 297:1379.
  52. Watts DH, Luthy DA, Benedetti TJ, et al. Intraperitoneal fetal transfusion under direct ultrasound guidance. Obstet Gynecol 1988; 71:84.
  53. Schumacher B, Moise KJ Jr. Fetal transfusion for red blood cell alloimmunization in pregnancy. Obstet Gynecol 1996; 88:137.
  54. Lindenburg IT, van Kamp IL, van Zwet EW, et al. Increased perinatal loss after intrauterine transfusion for alloimmune anaemia before 20 weeks of gestation. BJOG 2013; 120:847.
  55. Poissonnier MH, Picone O, Brossard Y, Lepercq J. Intravenous fetal exchange transfusion before 22 weeks of gestation in early and severe red-cell fetomaternal alloimmunization. Fetal Diagn Ther 2003; 18:467.
  56. Yinon Y, Visser J, Kelly EN, et al. Early intrauterine transfusion in severe red blood cell alloimmunization. Ultrasound Obstet Gynecol 2010; 36:601.
  57. Saade GR, Moise KJ, Belfort MA, et al. Fetal and neonatal hematologic parameters in red cell alloimmunization: predicting the need for late neonatal transfusions. Fetal Diagn Ther 1993; 8:161.
  58. De Boer IP, Zeestraten EC, Lopriore E, et al. Pediatric outcome in Rhesus hemolytic disease treated with and without intrauterine transfusion. Am J Obstet Gynecol 2008; 198:54.e1.
  59. Garabedian C, Rakza T, Drumez E, et al. Benefits of Delayed Cord Clamping in Red Blood Cell Alloimmunization. Pediatrics 2016; 137:e20153236.
  60. Janssens HM, de Haan MJ, van Kamp IL, et al. Outcome for children treated with fetal intravascular transfusions because of severe blood group antagonism. J Pediatr 1997; 131:373.
  61. Hudon L, Moise KJ Jr, Hegemier SE, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for the treatment of fetal hemolytic disease. Am J Obstet Gynecol 1998; 179:858.
  62. Dembinski J, Haverkamp F, Maara H, et al. Neurodevelopmental outcome after intrauterine red cell transfusion for parvovirus B19-induced fetal hydrops. BJOG 2002; 109:1232.
  63. Moise KJ, Whitecar PW. Antenatal therapy for haemolytic disease of the fetus and newborn. In: Alloimmune disorders in pregnancy. Anaemia, thrombocytopenia and neutropenia in the fetus and newborn, Hadley A, Soothill P (Eds), Cambridge University Press, Cambridge 2002.
  64. Harper DC, Swingle HM, Weiner CP, et al. Long-term neurodevelopmental outcome and brain volume after treatment for hydrops fetalis by in utero intravascular transfusion. Am J Obstet Gynecol 2006; 195:192.
  65. Grab D, Paulus WE, Bommer A, et al. Treatment of fetal erythroblastosis by intravascular transfusions: outcome at 6 years. Obstet Gynecol 1999; 93:165.
  66. Lindenburg IT, Smits-Wintjens VE, van Klink JM, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study. Am J Obstet Gynecol 2012; 206:141.e1.
  67. Gebb J, Dar P, Rosner M, Evans MI. Long-term neurologic outcomes after common fetal interventions. Am J Obstet Gynecol 2015; 212:527.e1.
  68. Wallace AH, Dalziel SR, Cowan BR, et al. Long-term cardiovascular outcome following fetal anaemia and intrauterine transfusion: a cohort study. Arch Dis Child 2017; 102:40.
  69. Dickinson JE, Sharpe J, Warner TM, et al. Childhood cardiac function after severe maternal red cell isoimmunization. Obstet Gynecol 2010; 116:851.